Core Viewpoint - CRISPR Therapeutics AG is at the forefront of gene editing, having received approval for its first gene editing treatment, CASGEVY, which targets sickle cell disease and beta-thalassemia [2][4]. Company Overview - CRISPR Therapeutics' stock is currently trading at approximately $36.31, showing little change since 2018, and investors from 2020 and 2021 may be facing losses [3][11]. - The company has a significant cash reserve of approximately $1.86 billion as of March 31, 2025, which is expected to support future growth [8]. Product and Market Potential - CASGEVY has been approved in eight jurisdictions and has 65 authorized treatment centers globally, with expectations for significant patient initiation growth by 2025 [6]. - The total addressable market for CASGEVY is estimated to be around 60,000 patients, although this is small compared to larger markets for diseases like cancer and diabetes [6][7]. Future Outlook - The company anticipates that 2026 will mark a turning point, generating enough revenue from CASGEVY to support sustainable growth for ongoing and future clinical trials [8]. - Analysts have a 12-month price target for CRISPR Therapeutics stock at $71.75, indicating a potential upside of 97.60% from the current price [10][12]. Investment Sentiment - Despite the current challenges, over 69% of CRSP stock is owned by institutional investors, and buying has outpaced selling for the last nine quarters [11][12]. - The stock is rated as a Moderate Buy by analysts, although it is not currently considered a top investment compared to other stocks [12][14].

It's been a long journey for CRISPR Therapeutics, which went public in 2016 and has declined over 80% from its 2021 peak. But now, the business could finally be nearing liftoff. Can buying today and holding it forever make you a millionaire? The first steps of commercialization, and what's next The company has shown its revolutionary technology can deliver life-changing therapies. Now, it's about whether CRISPR Therapeutics can replicate the success across its promising pipeline. Our genetics are like natur ...

Core Points - The article does not provide any specific insights or analysis related to companies or industries, focusing instead on the author's qualifications and disclosures [1][2][3]. Summary by Categories - **Author's Background**: The author has an extensive educational background in Electronics and Telecommunication Engineering, Computer Science, Business Management, and Computer Applications, with degrees from institutions in Ecuador, the USA, and Spain [1]. - **Disclosure of Interests**: The author discloses that there are no current stock or derivative positions in any mentioned companies and has no plans to initiate any such positions in the near future [2]. - **Seeking Alpha's Position**: The article clarifies that past performance does not guarantee future results and that the views expressed may not reflect those of Seeking Alpha as a whole [3].

Core Viewpoint - The article discusses the reliability of brokerage recommendations, particularly focusing on CRISPR Therapeutics AG (CRSP), and highlights the importance of using these recommendations in conjunction with other analytical tools like the Zacks Rank to make informed investment decisions [1][5][10]. Group 1: Brokerage Recommendations - CRISPR Therapeutics has an average brokerage recommendation (ABR) of 1.85, indicating a consensus between Strong Buy and Buy, based on recommendations from 28 brokerage firms [2]. - Among the 28 recommendations, 16 are classified as Strong Buy, accounting for 57.1%, while one is classified as Buy, making up 3.6% of the total [2]. Group 2: Limitations of Brokerage Recommendations - Studies indicate that brokerage recommendations often do not effectively guide investors towards stocks with the highest price increase potential due to analysts' inherent biases [5][10]. - Brokerage firms tend to exhibit a strong positive bias in their ratings, with five "Strong Buy" recommendations for every "Strong Sell" [6][10]. Group 3: Zacks Rank vs. ABR - The Zacks Rank is a proprietary stock rating tool that classifies stocks based on earnings estimate revisions, providing a more reliable indicator of near-term price performance compared to ABR [8][11]. - The Zacks Rank is updated more frequently and reflects changes in earnings estimates, making it a timely indicator of future price movements [12]. Group 4: Current Earnings Estimates for CRISPR Therapeutics - The Zacks Consensus Estimate for CRISPR Therapeutics has declined by 2.1% over the past month to -$5.09, indicating growing pessimism among analysts regarding the company's earnings prospects [13]. - This decline in earnings estimates has resulted in a Zacks Rank of 4 (Sell) for CRISPR Therapeutics, suggesting caution despite the favorable ABR [14].

Group 1 - The article discusses the analytical approach of a healthcare and tech stock analyst who combines clinical insights with valuation methods to identify investment opportunities [1] - The analyst specializes in scenario-based DCF modeling, sensitivity analysis, and Monte Carlo simulations to assess asymmetric risk-reward profiles [1] - The focus is on translating complex scientific and market dynamics into actionable investment theses, influenced by concepts from "Superforecasting" and "Fooled by Randomness" [1] Group 2 - The article emphasizes the importance of independent verification of information and conducting thorough research before making investment decisions [3] - It highlights that past performance is not indicative of future results and that no specific investment recommendations are provided [4]

Core Insights - CRISPR Therapeutics AG reported topline results from a Phase 1 trial for CTX310, targeting ANGPTL3 to address atherosclerotic heart disease risk factors [1][4] - The trial involved 10 patients across four cohorts, showing dose-dependent reductions in ANGPTL3, triglycerides (TGs), and low-density lipoprotein (LDL) [2][9] - CTX310 demonstrated a favorable safety profile with no severe adverse events reported [3] Trial Details - The trial included lean body weight-based doses of DL1 (0.1 mg/kg), DL2 (0.3 mg/kg), DL3 (0.6 mg/kg), and DL4 (0.8 mg/kg) with at least 30 days of follow-up for each participant [2] - A DL4 patient experienced an 82% reduction in triglycerides from a baseline of 1073 mg/dL, while a DL3 patient had an 81% reduction in LDL-C from a baseline of 256 mg/dL [9] Financials and Market Response - As of March 31, CRISPR reported cash, cash equivalents, and marketable securities totaling $1.85 billion [4] - Following the announcement, CRSP stock increased by 2.99% to $34.15 [7] Analyst Commentary - Chardan Research lowered the price target for CRISPR from $84 to $82, maintaining a Buy rating, indicating that while the topline results show safety and activity, further data in 2H25 will be crucial for assessing competitiveness [4][5] - The topline readout did not include patient-level data, which may introduce variability, but biomarker results align with benchmarks set by RNAi assets for ANGPTL3 [5]

Core Insights - CRISPR Therapeutics reported a first-quarter 2025 loss of $1.58 per share, wider than the Zacks Consensus Estimate of a loss of $1.27 per share, and compared to a loss of $1.43 per share in the same period last year [1] - Total revenues for the quarter were $0.86 million, significantly missing the Zacks Consensus Estimate of $5 million, and up from $0.5 million in the year-ago period [1] - The company's shares fell nearly 12% following the weak quarterly performance, with a year-to-date decline of 15.8%, compared to the industry decline of 2.3% [2] Financial Performance - Research and development expenses decreased by approximately 5% year over year to $72.5 million, attributed to reduced employee-related costs [6] - General and administrative expenses increased by 7.2% year over year to $19.3 million [6] - Collaboration expenses rose to $57.5 million in the first quarter from $47.0 million in the previous year, driven by costs related to the Casgevy therapy [6] - As of March 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $1.86 billion, down from $1.90 billion as of December 31, 2024 [7] Product Development and Pipeline - CRISPR Therapeutics and Vertex Pharmaceuticals' Casgevy therapy received approval for treating sickle cell disease and transfusion-dependent beta thalassemia in several countries [4] - Vertex reported Casgevy sales of $14.2 million in the first quarter, with over 65 authorized treatment centers activated and more than 90 patients initiating cell collection [5] - The company is evaluating two in-vivo candidates, CTX310 and CTX320, in separate phase I clinical studies targeting atherosclerotic heart disease [8] - Initial data from the CTX310 study showed dose-dependent decreases in LDL and TG levels, with peak reductions of up to 82% in TG and 81% in LDL [9] - CTX320 is targeting the LPA gene in patients with elevated Lp(a), with updates expected in the second quarter of 2025 [10] - CRISPR is also conducting phase I/II studies on next-generation allogeneic CAR T product candidates, CTX112 and CTX13, with updates anticipated in mid-2025 [10][11]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Switzerland Not Applicable (State or other jurisdiction of incorporation or organization) Baarerstrasse 14 6300 Zug, Switzerland Not Applicable (A ...

Exhibit 99.1 CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3 -Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low- density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, with a well-tolerated safety profile; presentation anticipated at a medical meeting in the second half of 2025- -CASGEVY® continues to gain mom ...

Core Insights - CRISPR Therapeutics has reported promising initial Phase 1 clinical data for CTX310™, showing significant dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with reductions of up to 82% in TG and 81% in LDL, alongside a well-tolerated safety profile [1][3][7] - The company continues to advance its innovative therapies, including CASGEVY®, which has over 65 authorized treatment centers activated globally and is expected to see significant patient growth in 2025 [1][6][7] - Ongoing clinical trials for CTX320™ and next-generation CAR T product candidates CTX112™ and CTX131™ are on track, with updates anticipated in 2025 [1][3][7] Financial Overview - As of March 31, 2025, the company has a strong balance sheet with approximately $1.86 billion in cash, cash equivalents, and marketable securities [1][18] - For the first quarter of 2025, research and development expenses were $72.5 million, a decrease from $76.2 million in the same period of 2024, while general and administrative expenses rose to $19.3 million from $18.0 million [18] - The net loss for the first quarter of 2025 was $136.0 million, compared to a net loss of $116.6 million in the first quarter of 2024 [18][27] Clinical Development Highlights - CTX310™ targets the ANGPTL3 gene, which is crucial for regulating LDL and TG levels, addressing a significant patient population in the U.S. affected by elevated LDL and TG levels [3][19] - The ongoing Phase 1 trial for CTX310 has shown that doses DL3 and DL4 resulted in reductions of up to 75% in ANGPTL3 levels, with no severe adverse events reported [3][4][7] - CTX320™ is also in a Phase 1 trial targeting the LPA gene, with updates expected in the second quarter of 2025 [1][3][7] Pipeline and Future Prospects - The company is advancing two preclinical programs, CTX340™ for refractory hypertension and CTX450™ for acute hepatic porphyrias, both in IND/CTA-enabling studies [1][3][19] - CASGEVY® has been approved in multiple jurisdictions for treating sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), with ongoing launches and reimbursement agreements enhancing patient access [1][6][14] - The company plans to present further clinical updates and data at medical meetings in the second half of 2025 [1][7]